End-of-life care is an important part of the care continuum for patients and the families of patients with terminal conditions or those encroaching upon old age. Palliative care is one option for end-of-life care and is specifically focused on symptom and pain management for patients with serious illnesses; it is not necessarily limited to patients in their last days or months of life and can be administered across a variety of care settings (from home to hospital)

“Vericred’s new provider network analytics suite offers a graphical, 360 degree view of a carrier’s own networks and those of their competitors,” said Michael W. Levin, Vericred’s co-founder and CEO. “Networks, broad and narrow, are a key health insurance product differentiator. Our network analytics suite, developed based on feedback from carrier partners, helps carriers identify competitive advantages and weaknesses and to curate their networks to strengthen their product offerings.”

iDentalSoft, a leading cloud-based dental practice management platform, today announced it has received a new round of funding led by FCA Venture Partners. Based in Nashville, FCA Venture Partners invests in fast-growing healthcare companies that streamline industry processes and improve the experience and quality of care for patients.

FCA Venture Partners is pleased to announce the completion of fundraising for its sixth fund, FCA Venture Partners VI, on April 27th. The Fund closed with $55M of committed capital and has already made investments in five portfolio companies. Consistent with its predecessor fund, FCA VI will focus on early to growth stage companies in the healthcare IT and technology sectors with disruptive, scalable business models.

Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, today announced that the private equity team at NovaQuest Capital Management, L.L.C. ("NovaQuest") has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital. The deep clinical, operational, and financial resources of NovaQuest will allow Clinical Ink to aggressively pursue growth opportunities and fuel investment in new products and operational capabilities.

The Oncology space offers an attractive market opportunity for the rapidly growing number of cancer-focused startups. The transition to value-based reimbursement is fueling this market opportunity by pressuring providers to improve processes and reduce costs.

We are pleased to announce that two FCA portfolio companies were recently featured on David William's Health Business Blog podcast. 

Absolute Antibody Ltd., an Oxford, UK-based company with a vision to make recombinant antibody technology accessible to all, and Kerafast Inc., a Boston, MA-based company with a mission to facilitate access to unique laboratory-made reagents, today announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.